Many drugmakers believe Amazon’s market entrance would positively disrupt the distribution system and create a more efficient pharmaceutical supply chain.
“Just like science is disrupted with gene therapy or novel treatments, I think the drug distribution channel also should be disrupted with improvements based on technology or efficiency,” Allergan CEO Brent Saunders said Wednesday during a call with analysts, according to CNBC.
Pfizer CEO Ian Read told CNBC Tuesday the company has not had direct conversations with Amazon, but is “more than willing to talk to anybody who can ensure” the efficiency of the drug distribution system.
Other drugmakers believe Amazon’s entrance could also reduce pharmacy benefit manufacturers’ role and power in the current drug supply chain.
“We’d be fools not to consider anyone who can disrupt the insurance/PBM stranglehold these companies have over patients and us,” a third drug company CEO, who wished to remain anonymous, told CNBC.
More articles on supply chain:
FDA approves adult treatment for lymphoma
10 most-read supply chain stories in October
Study: Competition did not prevent rise in cancer drug prices after launch
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
